tbuckley/cabot-search huggingface dataset:
Ammonium tetrathiomolybdate following ischemia/reperfusion injury: Chemistry, pharmacology, and impact of a new class of sulfide donor in preclinical injury models
Authors: Alex Dyson, Felipe Dal-Pizzol, Giovanni Sabbatini, Anna B. Lach, Federica Galfo, Juliano dos Santos Cardoso, Bruna Pescador Mendonça, Iain Hargreaves, Bernardo Bollen Pinto, Daniel I. Bromage, John F. Martin, Kevin P. Moore, Martin Feelisch, Mervyn Singer
Journal: PLoS Medicine (2017)

Early revascularization of ischemic organs is key to improving outcomes, yet consequent reperfusion injury may be harmful. Reperfusion injury is largely attributed to excess mitochondrial production of reactive oxygen species (ROS). Sulfide inhibits mitochondria and reduces ROS production. Ammonium tetrathiomolybdate (ATTM), a copper chelator, releases sulfide in a controlled and novel manner, and may offer potential therapeutic utility.
Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A
Authors: Yesim G. Dargaud, Robert Klamroth, Luminita Rusen, Jerzy Windyga, Johann Bichler, Sigurd Knaub, Claude Negrier
Journal: Blood (2016)
Liposomes with Silk Fibroin Hydrogel Core to Stabilize bFGF and Promote the Wound Healing of Mice with Deep Second‐Degree Scald
Authors: He‐Lin Xu, Pian‐Pian Chen, De‐Li ZhuGe, Qun‐Yan Zhu, Bing‐Hui Jin, Bi‐Xin Shen, Jian Xiao, Ying‐Zheng Zhao
Journal: Advanced Healthcare Materials (2017)

Abstract How to maintain the stability of basic fibroblast growth factor (bFGF) in wounds with massive wound fluids is important to accelerate wound healing. Here, a novel liposome with hydrogel core of silk fibroin (SF‐LIP) is successfully developed by the common liposomal template, followed by gelation of liquid SF inside vesicle under sonication. SF‐LIP is capable of encapsulating bFGF (SF‐bFGF‐LIP) with high efficiency, having a diameter of 99.8 ± 0.5 nm and zeta potential of −9.41 ± 0.10 mV. SF‐LIP effectively improves the stability of bFGF in wound fluids. After 8 h of incubation with wound fluids at 37 °C, more than 50% of free bFGF are degraded, while only 18.6% of the encapsulated bFGF in SF‐LIP are destroyed. Even after 3 d of preincubation with wound fluids, the cell proliferation activity and wound healing ability of SF‐bFGF‐LIP are still preserved but these are severely compromised for the conventional bFGF‐liposome (bFGF‐LIP). In vivo experiments reveal that SF‐bFGF‐LIP accelerates the wound closure of mice with deep second‐degree scald. Moreover, due to the protective effect and enhanced penetration ability, SF‐bFGF‐LIP is very helpful to induce regeneration of vascular vessel in comparison with free bFGF or bFGF‐LIP. The liposome with SF hydrogel core may be a potential carrier as growth factors for wound healing.
Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML)
Authors: Sandrine Niyongere, Nolwenn Lucas, Samir Sansil, Christopher L Cubitt, Maria E. Balasis, Jodi Kroeger, Qing Zhang, John J Ceremsak, Elliot Stieglitz, YuLong Zhao, Markus Ball, Rami S. Komrokji, Alan F List, Valeria Santini, Eric Solary, Eric Padron
Journal: Blood (2016)
A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.
Authors: Aaron Richard Hansen, Geoffrey Shapiro, Khanh T Do, Rajiv Kumar, Juan Martin-Liberal, Celestia S. Higano, Kari Braun Wisinski, Emma Jane Dean, Elisabeth I. Heath, Dana E. Rathkopf, Mark David Linch, Simon T Barry, Wolfram Brugger, Elza De Bruin, Steve Colebrook, Teresa Klinowska, Patrick D Mitchell, Ganesh Moorthy, Johann S. De Bono, Lillian L. Siu
Journal: Journal of Clinical Oncology (2017)

2570 Background: Loss of PTEN function leads to increased PI3Kβ signalling. AZD8186 (AZD) exhibits significant anti-tumour activity in PTEN-deficient preclinical models, particularly when combined with anti-androgens or the dual mTORC1/2 inhibitor vistusertib (AZD2014). Here we report on the dose-finding part of this Phase 1 study. Methods: AZD single agent was administered twice daily (BD) in 3 different schedules (5 days on/ 2 days off, 2 days on/ 5 days off and continuous). Escalating doses of AZD were evaluated in cohorts of 3-6 patients treated until progression, unacceptable toxicity, or consent withdrawal. Accrual is ongoing in the combination arms with vistusertib or abiraterone acetate. Results: As of 16 Jan 2017, 87 patients have received AZD at doses of 30–360 mg BD, with 28 confirmed as PTEN deficient (IHC). The selected RP2D for the 5 days on/2 days off monotherapy schedule is 60 mg BD. PK parameters show that systemic exposures to AZD and its major active metabolite increase in a dose proportional manner. 69 serious adverse events (SAEs) were reported in 31 patients on AZD monotherapy with 23 SAEs considered possibly related to AZD. In the 5/2 schedule: 5 dose limiting toxicities (G3 rash with ≥G2 fever and/or chills) were observed in 5 patients at doses of 120-360mg. Adverse events ≥G1 in &gt; 20% included diarrhoea, nausea, fatigue, LFT elevations and decreased appetite. 20 patients remained on study for &gt; 100 days. Dose-dependent target inhibition has been demonstrated in surrogate tissue (platelets). Evaluation of direct tumour target engagement in paired biopsies is currently ongoing. Preliminary efficacy: Confirmed PRs seen in a CRPC patient (BRCA2 and androgen receptor mutant) treated in combination with vistusertib (on study for 411 days) and in one ongoing monotherapy PTEN-deficient colorectal cancer patient (on study &gt; 329 days). Updated data will be presented. Conclusions: AZD has potential for treatment of PTEN-deficient tumours. Investigation of the safety/tolerability and preliminary efficacy in combination with vistusertib or abiraterone acetate is continuing. Clinical trial information: NCT01884285.
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial
Authors: Karen E Anderson, David Stamler, Mat D Davis, Stewart A Factor, Robert A Hauser, Jouko Isojärvi, L Fredrik Jarskog, Joohi Jimenez-Shahed, Rajeev Kumar, Joseph P McEvoy, Stanislaw Ochudlo, William G Ondo, Hubert H Fernandez
Journal: The Lancet Psychiatry (2017)
Biomarker analysis of patients treated with anti-CD19 chimeric antigen receptor (CAR) T cells.
Authors: Adrian Bot, James Kochenderfer, Armen Mardiros, Arianne Perez, Lynn Navale, Richard Chang, Yueh Wei-Shen, Sean Yoder, Jia Xiao-Chi, Steven A. Rosenberg, William Y. Go, Jeffrey S. Wiezorek, Margo Roberts, David D. Chang
Journal: Journal of Clinical Oncology (2015)

3028 Background: CAR engineered autologous T cell therapy has shown promising efficacy in B cell malignancies in an ongoing phase 1 study (Kochenderfer et al. J Clin Oncol 2014, ASH 2014). Anti-CD19 CAR T cell product characteristics and pharmacodynamic markers from patients in this study were correlated with clinical results. Methods: Patients with relapsed/refractory B cell malignancies received conditioning with fludarabine and cyclophosphamide, then anti-CD19 CAR T cells engineered with a CAR comprising CD28 and CD3-zeta signaling domains. Product T cells were characterized as such, or upon co-culture with CD19+ tumor cells, by flow cytometry and multiplex cytokine analysis. Pre- and post-CAR T cell infusion peripheral blood mononuclear cells (PBMCs) and sera were also evaluated. Results: To date, 11 anti-CD19 CAR T cell products, and PBMCs and serum samples from 7 patients have been evaluated. Five had an objective response to anti-CD19 CAR T cell treatment. Product T cells comprised central memory, peripheral memory and effector T cells. Upon co-culture with CD19+ tumor cells, these CAR T cells produced T1, T2, pro-inflammatory, homeostatic and effector cytokines, and chemokines. The treated patients showed induction of key homeostatic and inflammatory cytokines upon conditioning, as well as increased levels of immune effector molecules (granzymes, perforin) during the first 2 weeks after CAR T cell treatment. Additionally, the clinical responders showed in vivo expansion of CAR+ T cells to a range of 15-300 CAR+ PBMC/µL within 14 days after T cell treatment. Further analyses are ongoing. Conclusions: Detailed biomarker analysis from patients treated with anti-CD19 CAR T cells, may provide insight to clinical outcomes and guide the design of T-cell therapies.
Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial
Authors: Anita Mahajan, Salmaan Ahmed, Mary Frances McAleer, Jeffrey S Weinberg, Jing Li, Paul Brown, Stephen Settle, Sujit S Prabhu, Frederick F Lang, Nicholas Levine, Susan McGovern, Erik Sulman, Ian E McCutcheon, Syed Azeem, Daniel Cahill, Claudio Tatsui, Amy B Heimberger, Sherise Ferguson, Amol Ghia, Franco Demonte, Shaan Raza, Nandita Guha-Thakurta, James Yang, Raymond Sawaya, Kenneth R Hess, Ganesh Rao
Journal: The Lancet Oncology (2017)
A Risk Calculator for Bipolar Spectrum Disorder in Youth at Familial Risk
Authors: Esther Mesman, Manon H. J. Hillegers
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Local Cues Establish and Maintain Region-Specific Phenotypes of Basal Ganglia Microglia
Authors: Lindsay M. De Biase, Kornel E. Schuebel, Zachary H. Fusfeld, Kamwing Jair, Isobel A. Hawes, Raffaello Cimbro, Hai-Ying Zhang, Qing-Rong Liu, Hui Shen, Zheng-Xiong Xi, David Goldman, Antonello Bonci
Journal: Neuron (2017)
Benchmarking: contexts and details matter
Authors: Siyuan Zheng
Journal: Genome biology (2017)

Benchmarking is an essential step in the development of computational tools. We take this opportunity to pitch in our opinions on tool benchmarking, in light of two correspondence articles published in Genome Biology. Please see related Li et al. and Newman et al. correspondence articles: www.dx.doi.org/10.1186/s13059-017-1256-5 and www.dx.doi.org/10.1186/s13059-017-1257-4
BMA annual meeting: Pregabalin must be made a controlled drug, BMA says
Authors: Tom Moberly
Journal: BMJ (2017)

Pregabalin should be reclassified as a controlled drug to tackle widespread problems of misuse and addiction, the BMA has said.

Delegates at the BMA’s annual representative meeting in Bournemouth on 28 June voted in favour of a motion saying that the BMA should “lobby the appropriate authorities to make pregabalin a controlled drug.”

Pregabalin is currently a prescription only drug and is licensed for the treatment of neuropathic pain and …
European Commission issues advice on use of antimicrobials
Authors: Rory Watson
Journal: BMJ (2017)

Guidelines on the use of antimicrobials in human health have been issued for the first time by the European Commission. They provide specific advice for the medical profession, national authorities, researchers, the pharmaceutical industry, and the general public.

The guidelines are part of a package of measures in a new action plan to tackle antimicrobial resistance (AMR) presented by the commission in Brussels on 29 June.

Launching the five year plan, Vytenis Andriukaitis, the health and food safety commissioner, said: “Antimicrobial resistance is a growing global threat and if we do …
Availability of Definitive Hospital Care for Children
Authors: Urbano L. França, Michael L. McManus
Journal: JAMA Pediatrics (2017)

<h3>Importance</h3> Timely and efficient access to hospital care is essential for the health and well-being of children. As insurance networks, accountable care organizations, and alternative payment methods evolve, these new systems of care must continue to serve the needs of children. <h3>Objective</h3> To test the hypothesis that the availability of definitive pediatric hospital care is significantly more limited than adult care and is decreasing disproportionately. <h3>Design</h3> This study used case mix data during fiscal years 2004 through 2014 to measure transfer frequency and identify the site of care completion for all patients seen in acute care hospitals throughout Massachusetts. Patterns of care among children were then compared with patterns of care among adults. Participants were all patients seen in an emergency department or admitted to a hospital from 2004 through 2014, including more than 34 million encounters. <h3>Main Outcomes and Measures</h3> Hospital Capability Index and Regionalization Index for all acute care hospitals and all conditions within the Clinical Classifications Software of the Healthcare Cost and Utilization Project. <h3>Results</h3> Over the study period, the Commonwealth of Massachusetts hospital system was composed of 66 acute care hospitals. After excluding newborns and mental health conditions, there were 34 511 312 encounters, with 25 226 014 emergency department visits and 9 285 298 observation or full admissions. From 2004 through 2014, care for adults and children concentrated among hospitals but much more so for pediatric care. The number of children requiring care in more than one hospital increased 36.2% (from 7190 to 9793). The median (interquartile range [IQR]) Hospital Capability Index, reflecting the likelihood of a hospital completing a patient's care without transfer, decreased 10.8% (from 0.74 [IQR, 0.65-0.81] to 0.66 [IQR, 0.53-0.76]) for adult care and 65.0% (0.20 [IQR, 0.05-0.34] to 0.07 [IQR, 0.01-0.23]) for pediatric care. Almost all of the shift was from nonacademic to academic hospitals. The median Regionalization Index, reflecting the degree to which care for specific conditions is regionalized, was very high for pediatric conditions and further increased from 0.79 (IQR, 0.67-0.91) to 0.87 (IQR, 0.80-0.91). Over the same decade, the mean Regionalization Index for adult conditions was low and increased modestly from 0.25 (IQR, 0.14-0.39) to 0.32 (IQR, 0.19-0.46). Among pediatric conditions, more than 75% were highly regionalized in 2014 compared with fewer than 50% in 2004. <h3>Conclusions and Relevance</h3> Pediatric hospital care has become increasingly concentrated, and many children with common conditions are now less frequently treated in the community. This finding has significant implications for systemwide capacity management and should be specifically accounted for in public health activities, disaster planning, and determinations of network adequacy.
The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis
Authors: P Garrido Castro, E H J van Roon, S S Pinhanços, L Trentin, P Schneider, M Kerstjens, G te Kronnie, O Heidenreich, R Pieters, R W Stam
Journal: Leukemia (2017)
Reply: The Choice of Indicators for Obstructive Sleep Apnea Treatment Outcome Evaluation: A Matter of Time-Dependent Response?
Authors: Frédéric Gagnadoux, Jean-Louis Pépin, Bruno Vielle, Vanessa Bironneau, Frédérique Chouet-Girard, Sandrine Launois, Nicole Meslier, Jean-Claude Meurice, Xuan-Lan Nguyen, Audrey Paris, Pascaline Priou, Renaud Tamisier, Wojciech Trzepizur, François Goupil, Bernard Fleury
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Abstract 332: Exercise Training Protects Against Acute Myocardial Infarction via Improving Myocardial Energy Metabolism and Mitochondrial Biogenesis
Authors: Lichan Tao, Yihua Bei, Haifeng Zhang, Yanli Zhou, Jingfa Jiang, Ping Chen, Shutong Shen, Junjie Xiao, Xinli Li
Journal: Circulation Research (2015)

Acute myocardial infarction (AMI) represents a major cause of morbidity and mortality worldwide. Exercise has been proved to reduce myocardial ischemia-reperfusion (I/R) injury. However it remains unclear whether, and (if so) how, exercise could protect against AMI. Methods: Mice were trained using a 3-week swimming protocol, and then subjected to left coronary artery (LCA) ligation, and finally sacrificed 24 h after AMI. Results: Exercise training reduces myocardial infarct size and abolishes AMI-induced autophagy and apoptosis. MI leads to a shift from fatty acid to glucose metabolism in the myocardium with a downregulation of PPAR-α and PPAR-γ. Also, AMI induces an adaptive increase of mitochondrial DNA replication and transcription in the acute phase of MI, accompanied by an activation of PGC-1α signaling. Exercise abolishes the derangement of myocardial glucose and lipid metabolism and further enhances the adaptive increase of mitochondrial biogenesis. Conclusion: Exercise training protects against AMI-induced acute cardiac injury through improving myocardial energy metabolism and enhancing the early adaptive change of mitochondrial biogenesis.
Newly-Generated Regulatory B- and T-Cells Are Associated with Clinical Improvement and Reversal of Dermal Fibrosis in Systemic Sclerosis Patients after Autologous Hematopoietic Stem Cell Transplantation
Authors: Lucas C M Arruda, João R Lima-Júnior, Emmanuel Clave, Daniela A Moraes, Corinne Douay, Isabelle Fournier, Hélène Moins-Teisserenc, Dimas Tadeu Covas, Kelen Malmegrim, Dominique Farge, Leandra Ramalho, Antoine Toubert, Maria Carolina Oliveira
Journal: Blood (2016)
Assessment of the ITMIG Statement on the WHO Histological Classification and of the Eighth TNM Staging of Thymic Epithelial Tumors of a Series of 188 Thymic Epithelial Tumors
Authors: Alexandra Meurgey, Nicolas Girard, Claire Merveilleux du Vignaux, Jean-Michel Maury, François Tronc, Françoise Thivolet-Bejui, Lara Chalabreysse
Journal: Journal of Thoracic Oncology (2017)
Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early<i>TOP2A</i>-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
Authors: Bent Ejlertsen, Malgorzata K. Tuxen, Erik Hugger Jakobsen, Maj-Britt Jensen, Ann Soegaard Knoop, Inger Højris, Marianne Ewertz, Eva Balslev, Hella Danø, Peter Michael Vestlev, Julia Kenholm, Dorte L. Nielsen, Troels Bechmann, Michael Andersson, Søren Cold, Hanne Melgaard Nielsen, Else Maae, Dorte Carlsen, Henning T. Mouridsen
Journal: Journal of Clinical Oncology (2017)

Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a non–anthracycline-based regimen in TOP2A-normal patients. Patients and Methods In this multicenter, open-label, phase III trial, 2,012 women with early TOP2A-normal breast cancer and at least one high-risk factor were randomly assigned to receive six cycles of docetaxel (75 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) every 3 weeks (DC) or three cycles of epirubicin (90 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) followed by three cycles of docetaxel (100 mg/m 2 ; EC-D). The primary end point was disease-free survival (DFS) after a median of 5 years of follow-up. Secondary end points were patient-reported toxicity, overall survival (OS), and distant disease–free survival. Results At a median estimated potential follow-up of 69 months, 5-year DFS was 87.9% (95% CI, 85.6% to 89.8%) in the EC-D arm and 88.3% (95% CI, 86.1% to 90.1%) in the DC arm. There was no significant difference in the risk of DFS events (hazard ratio [HR], 1.00; 95% CI, 0.78 to 1.28; P = 1.00), distant disease–free survival (HR, 1.12; 95% CI, 0.86 to 1.47; P = .40), or mortality (HR, 1.15; 95% CI, 0.83 to 1.59; P = .41) in the intent-to-treat analysis. A significant interaction between menopausal status and treatment group was observed for DFS ( P = .04) but not for OS ( P = .07). Patients with grade 3 tumors derived most benefit from DC, and patients with grade 1 to 2 tumors derived most benefit from EC-D (DFS: interaction P = .02; and OS: interaction P = .03). Patients receiving EC-D reported significantly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral neuropathy, whereas edema was more frequent after DC. Conclusion This study provides evidence to support no overall outcome benefit from adjuvant anthracyclines in patients with early TOP2A-normal breast cancer.
What's hot that the other lot got
Authors: Candy Lee
Journal: Thorax (2014)

In this multicentre, prospective cohort study ( N Engl J Med 2014;370:139–49), the clinical safety and efficacy of upper airway stimulation in 126 patients with moderate to severe obstructive sleep apnoea who had difficulty adhering to CPAP were evaluated. Upper airway pacing of the hypoglossal nerve, coordinated with ventilatory effort, led to significant improvement in subjective and objective measures of the severity of obstructive sleep apnoea. Median apnoea-hypopnoea index at 12 months reduced 68%, from 29.3 events/h to 9.0 events/h (p<0.001). Oxygen desaturation index decreased 70%, from 25.4 events/h to 7.4 events/h (p<0.001). A reduction of sleep apnoea symptoms and improved quality of life were reported by patients. There is a possible role for this treatment in the future, although it is unlikely to replace CPAP as first line therapy.

Optimal pulmonary …
The Sense of Smell Impacts Metabolic Health and Obesity
Authors: Celine E. Riera, Eva Tsaousidou, Jonathan Halloran, Patricia Follett, Oliver Hahn, Mafalda M.A. Pereira, Linda Engström Ruud, Jens Alber, Kevin Tharp, Courtney M. Anderson, Hella Brönneke, Brigitte Hampel, Carlos Daniel de Magalhaes Filho, Andreas Stahl, Jens C. Brüning, Andrew Dillin
Journal: Cell Metabolism (2017)
Metastatic endophthalmitis and thyroid abscess complicating Klebsiella pneumoniae liver abscess
Authors: Seon-Jae Kim, Seong Taek Chu, Keun Sook Lee, Seung Woo Nam, Jong Kyoung Choi, Joo Won Chung, Hyeok Choon Kwon
Journal: Clinical and Molecular Hepatology (2017)

The thyroid is resistant to infection due to its anatomical and physiological characteristics. We present a rare case of invasive liver abscess with metastatic thyroid abscess and endogenous endophthalmitis in a previously healthy 55-year-old female patient without diabetes or other medical illness. This report raises an important question of the virulence of Klebsiella pneumoniae as an increasingly common causative agent of liver abscess.
Collection of Peripheral Blood Stem Cells in 118 Small Children Weighing 20 Kg or less: Experience of a Single Centre
Authors: Jianyun Wen, Yuelin He, Libai Chen, Jing Du, Zhiyong Peng, Jianyun Liao, Huaying Liu, Xiaohui Zhou, Chunfu Li, Xuedong Wu
Journal: Blood (2016)
YM155 Induces Apoptosis through Proteasome-Dependent Degradation of MCL-1 in Primary Effusion Lymphoma
Authors: Yuki Kojima, Fumihiko Hayakawa, Takanobu Morishita, Keiki Sugimoto, Mizuho Iwase, Hideyuki Yamamoto, Daiki Hirano, Naoto Imoto, Seiji Okada, Hitoshi Kiyoi
Journal: Blood (2016)